Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE – COALITION VIII randomised clinical trialResearch in context

Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE – COALITION VIII randomised clinical trialResearch in context

Summary: Background: COVID-19 progression is associated with an increased risk of arterial and venous thrombosis. Randomised trials have demonstrated that anticoagulants reduce the risk of thromboembolism in hospitalised patients with COVID-19, but a benefit of routine anticoagulation has not been...

Full description

Bibliographic Details
Main Authors: Álvaro Avezum, Haliton Alves Oliveira Junior, Precil Diego M.M. Neves, Lucas Bassolli O. Alves, Alexandre B. Cavalcanti, Regis G. Rosa, Viviane C. Veiga, Luciano C.P. Azevedo, Sérgio Luiz Zimmermann, Odilson Marcos Silvestre, Raphael Cruz Seabra Prudente, Adrian Paulo Morales Kormann, Frederico Rafael Moreira, Icaro Boszczowski, Edgar de Brito Sobrinho, André da Silva e Souza, Renato Seligman, Bruno de Souza Paolino, Alvaro Razuk, Audes Diogenes de Magalhaes Feitosa, Pedro Luiz Monteiro Belmonte, Priscila Freitas das Neves Gonçalves, Mauro Esteves Hernandes, Ariovaldo Leal Fagundes, José Maria Sarmet Esteves, Alexandre Pereira Tognon, John Eikelboom, Otávio Berwanger, Renato D. Lopes, Gustavo B.F. Oliveira
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:EClinicalMedicine
Subjects:
Anticoagulation
COVID-19
Outpatients
Randomised clinical trial
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023001815

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023001815

Similar Items